$2.85
-0.05 (-1.72%)
Open$2.90
Previous Close$2.90
Day High$2.94
Day Low$2.73
52W High$4.54
52W Low$1.35
Volume—
Avg Volume1.11M
Market Cap256.02M
P/E Ratio—
EPS$-1.22
SectorBiotechnology
Analyst Ratings
Buy
20 analysts
Price Target
+349.5% upside
Current
$2.85
$2.85
Target
$12.81
$12.81
$8.62
$12.81 avg
$14.59
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 41.02M | 32.26M | 30.54M |
| Net Income | -162,023,336 | -114,684,233 | 4.38M |
| Profit Margin | -395.0% | -375.3% | 14.4% |
| EBITDA | -158,843,237 | -118,679,571 | 9.59M |
| Free Cash Flow | — | — | 5.15M |
| Rev Growth | +27.2% | +27.2% | +16.6% |
| Debt/Equity | 2.15 | 2.15 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |